We divided unfavorable chemotherapy responses (PD) and favorable responses (PR+SD) as two cohorts, and found that the mRNA expression level of CD4/IFNGR2/CD68/CSF1R could predict favorable neoadjuvant chemotherapy responses in OSA target lesions (Figure 6B). Here, CD68 is linked to obstructive sleep apnea syndrome.